Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Sackler family has earned billions from the sale of OxyContin and the backlash against the family has increased in-fighting, according to reports.
The National Institute of Health Research has announced £135m of funding for new research projects across the UK to tackle some of the biggest health conditions, including dementia.
Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel.
BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease
Allergy Therapeutics plc provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.
Heidelberg Pharma AG published its financial report on the first six months of 2019
The World Health Organization developed a five-year plan to promote regulatory collaboration and reliance around the world and to assist national regulatory authorities in solving related issues.
Some members of the Trump administration worried that passing the rebates directly to consumers would cost the federal government too much in the long run.
Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal